Drug Profile
Bortezomib - Dr. Reddy's Laboratories
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories
- Class Amides; Anti-ischaemics; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules; Vascular disorder therapies
- Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Mantle-cell lymphoma; Multiple myeloma
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-myeloma(Second-line therapy or greater) in India (Parenteral, Injection)
- 28 Nov 2022 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-myeloma(First-line therapy) in India (Parenteral, Injection)
- 16 Jan 2020 Clinical development is ongoing in India (CTRI/2019/09/021455)